Publicaciones en colaboración con investigadores/as de Moscow City Oncology Hospital №62 (2)

2019

  1. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study

    Journal of Clinical Oncology

2018

  1. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 1, pp. 115-126